Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Decrease in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 16,792 shares, a decrease of 38.9% from the July 15th total of 27,481 shares. Based on an average trading volume of 12,983 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.5% of the company’s stock are short sold.

Pulmatrix Trading Down 0.8%

Shares of PULM stock traded down $0.01 during trading hours on Tuesday, hitting $1.55. 6,687 shares of the company were exchanged, compared to its average volume of 42,460. The stock has a market capitalization of $5.65 million, a price-to-earnings ratio of -1.39 and a beta of 1.91. The firm has a fifty day simple moving average of $1.62 and a 200 day simple moving average of $1.74. Pulmatrix has a 52-week low of $1.16 and a 52-week high of $5.50.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Pulmatrix in the second quarter worth approximately $93,000. DRW Securities LLC bought a new stake in Pulmatrix during the fourth quarter valued at approximately $46,000. Finally, Dimensional Fund Advisors LP bought a new stake in Pulmatrix during the third quarter valued at approximately $52,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).